검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Med (injection of scAAV2-P1ND4v2 5.81 X10e9 vg, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)) Byron Lam·Leber's Hereditary Optic Neuropath… ORR 73.59% |
|---|---|
Overview Program | injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med) |
Overview Company | Byron Lam |
Overview Modality | CGT |
Overview Target | Leber's Hereditary Optic Neuropathy |
Overview Indication | Leber's Hereditary Optic Neuropathy |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | target, and multi‑pathway |
MoA Biomarker | biomarker and a new molecular target for IVDD, thereby providing a foundation for future functional and mecha |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Dual prodrugs of N 4 -hydroxycytidine with ProTide and ester modifications as anti-SARS-CoV-2 agents.. Molnupiravir, an oral prodrug of β-D-N 4 -hydroxycytidine (NHC), is a broad-spectrum antiviral agent. However, its clinical efficacy is hampered by suboptimal plasma stability and inefficient intracellular monophosphorylation. To circumvent these pharmacological limitations, a novel series … |
Clinical Primary efficacy | ORR 73.59% |
Clinical ORR | 73.59% |
Clinical Result source | ClinicalTrials.gov NCT03031678 |
Clinical Data Tier / Score | A · 53 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Med (injection of scAAV2-P1ND4v2 5.81 X10e9 vg, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)) Byron Lam·Leber's Hereditary Optic Neuropath… ORR 73.59% |
|---|---|
Overview Program | injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med) |
Overview Company | Byron Lam |
Overview Modality | CGT |
Overview Target | Leber's Hereditary Optic Neuropathy |
Overview Indication | Leber's Hereditary Optic Neuropathy |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | target, and multi‑pathway |
MoA Biomarker | biomarker and a new molecular target for IVDD, thereby providing a foundation for future functional and mecha |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Dual prodrugs of N 4 -hydroxycytidine with ProTide and ester modifications as anti-SARS-CoV-2 agents.. Molnupiravir, an oral prodrug of β-D-N 4 -hydroxycytidine (NHC), is a broad-spectrum antiviral agent. However, its clinical efficacy is hampered by suboptimal plasma stability and inefficient intracellular monophosphorylation. To circumvent these pharmacological limitations, a novel series … |
Clinical Primary efficacy | ORR 73.59% |
Clinical ORR | 73.59% |
Clinical Result source | ClinicalTrials.gov NCT03031678 |
Clinical Data Tier / Score | A · 53 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교